Topics: Pharmaceutical Industry | Practice Tools and Tips | Psychopharmacology Tips | Women's Issues in Psychiatry

We’ve been hearing for some time now about the FDA’s plans to revise the long-standing categories A, B, C, D, and X designations for risk of using medications in pregnancy. The new rule (referred to as PLLR for Pregnancy and Lactation Labeling Rule) was proposed in 2008, finalized in 2014, and implementation began during the summer of 2015.

Topics: Mood Stabilizers | Pharmaceutical Industry | Practice Tools and Tips | Psychopharmacology Tips | Women's Issues in Psychiatry

Dr. Vivien Burt discusses mood disorders and pregnancy. It’s now pretty widely recognized that pregnancy does not protect against mental illness, and the postpartum period is certainly a time of very high vulnerability for women, especially if they’ve had a history of psychiatric illness.

Topics: Antidepressants

Dr. Simone Vigod describes her approach to prescribing medications during pregnancy. She starts by assessing the severity of the symptoms and the impact on function. Women usually fall into two categories: those who are not on medication and have become symptomatic, and those who have been taking medication, who are perhaps in remission, and are unsure about going off medication during pregnancy.

Topics: Antipsychotics

Excessive salivation is a common and troubling adverse effect of clozapine therapy, occurring in about 30% of patients. Recently, Israeli researchers evaluated another potential treatment, metoclopramide (Reglan), which is a drug for nausea and other gastrointestinal problems. Since metoclopramide commonly causes dry mouth, the authors of this paper reasoned that it might work for clozapine-induced hypersalivation.

Topics: OCD | Research Update

Skin picking disorder is a compulsive behavior affecting 5% of people. N-acetylcysteine is an antioxidant that increases glutamate, and studies have shown that it is effective for excoriation’s sister disorder, trichotillomania (hair pulling). These data prompted investigators to try N-acetylcysteine in the treatment of SPD.

Topics: Addiction | Depressive Disorder | Research Update

When patients become severely suicidal, we have few good treatment options. Recognizing the need for more options, Israeli researchers studied the use of very low doses of buprenorphine in suicidal patients. Patients with suicidal ideation were recruited from four medical centers.

Topics: Depression | Research Update

In the summer of 2011, the Food and Drug Administration (FDA) reported that post-marketing surveillance showed that patients taking greater than 40 mg/day of citalopram were at greater risk of QT prolongation. Shortly thereafter, the Department of Veterans Affairs (VA) alerted its providers to this warning. VA researchers recently published a study detailing the results of this warning on patients.

After reading the issue, click here to take the CME test and earn your certificate.